Clinical Trials Logo

Polyp, Colonic clinical trials

View clinical trials related to Polyp, Colonic.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05022719 Completed - Colorectal Cancer Clinical Trials

Technical Feasibility Evaluation of Mucosal Staining During Colon Capsule Endoscopy (CCE) Procedure in Colorectal Cancer (CRC) High Risk Population, When Using MB-MMX

Start date: October 4, 2021
Phase: N/A
Study type: Interventional

A prospective, single-center, single-arm, non-randomized, post-market pilot study evaluating the technical feasibility of mucosal staining during COLON2 Capsule Endoscopy (CCE) procedure in population at high risk for Colorectal Cancer (CRC), when using MB-MMX (Methylene Blue). Up to 15 subjects will be enrolled in 1 center located in Spain. Study duration- up to 10 months from study approval.

NCT ID: NCT04444947 Completed - Polyp, Colonic Clinical Trials

Influencing Factors in Patients With Colorectal and Gastric Polyps a Retrospective Study

Start date: February 20, 2019
Phase:
Study type: Observational [Patient Registry]

The identification of risk factors of colorectal/gastric polyp is more helpful for preventing colorectal cancer. And modifiable factors (such as high-fat diet, abnormal blood lipid, smoking, lack of exercise, obesity), and unmodifiable factors (including age, gender, race, familial adenomas, genetic)) can affect the risk of polyps. Thus early studying risk factors are the key to improving prognosis. what's more, early detection and timely treatment have important clinical significance for preventing and reducing the occurrence of gastrointestinal cancer.

NCT ID: NCT03309683 Completed - Bleeding Clinical Trials

Clip Placement Following Colonic Endoscopic Mucosal Resection (EMR)

CLIPPER
Start date: March 5, 2018
Phase: N/A
Study type: Interventional

Study design: A national, multi-center, patient-blinded, randomized clinical trial. Study population: Patients undergoing EMR with a moderate to severe risk (right sided colon, ≥2cm) of developing Delayed Bleeding (DB). Intervention: PC will be compared to standard care (no PC). Main study endpoints: Primary endpoint is the incidence of DB. Secondary endpoints are cost-effectiveness, quality of life and (severe) adverse events related to PC, adenoma recurrence and risk factors for DB.